NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies said today in its annual report that a commercialization agreement it had with Illumina will terminate on June 30, 2016.

The decision is the outcome of an arbitration demand that Illumina brought against Oxford Nanopore in 2011 over the terms of the agreement. The two firms dismissed the suit in April and agreed to amend the commercialization deal, according to Oxford's annual report.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

Feb
21
Sponsored by
Oracle Health Sciences

This webinar will cover best practices for integrating data from multiple clinical and genomic sources for clinical decision support.